Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nab-paclitaxel · 1 trial · 5 indications
Weight stability will be documented as percent weight change at 3 months compared to baseline.
| Arm | Type | Description |
|---|---|---|
| Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | EXPERIMENTAL | Patients receive gemcitabine/nab-paclitaxel combination chemotherapy on days 1, 8 and 15, and telotristat ethyl PO QD, BID, or TID on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Group 2 (gemcitabine/nab-paclitaxel) | ACTIVE_COMPARATOR | Patients receive gemcitabine/nab-paclitaxel chemotherapy (at the discretion of the investigator) on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | Given gemcitabine/nab-paclitaxel combination therapy |
| Nab-paclitaxel | DRUG | Given gemcitabine/nab-paclitaxel combination therapy |
| Telotristat Ethyl | DRUG | Given PO |
Inclusion Criteria: * GROUP 1 (Telotristat ethyl treatment group): Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separat...
Nab-paclitaxel is being studied for use in locally advanced unresectable pancreatic adenocarcinoma, a type of pancreatic cancer that cannot be removed with surgery. It is an investigational small molecule oncology drug currently in Phase 2 clinical development for this indication.
Nab-paclitaxel is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LXRX. The company is conducting clinical research to evaluate the drug's potential in treating pancreatic cancer.
Nab-paclitaxel is in Phase 2 clinical development for locally advanced unresectable pancreatic adenocarcinoma. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy.
Nab-paclitaxel is associated with clinical trial NCT03910387, titled "Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer." This Phase 2 study has been completed and enrolled 23 participants in the United States.
Nab-paclitaxel is the drug being studied in a clinical trial that also involves telotristat ethyl. The trial NCT03910387 evaluates telotristat ethyl's effect on weight stability in patients with advanced pancreatic cancer, including those with locally advanced unresectable disease.